Back to Studies

P1047 / Safety And Immunogenicity Of QHPV In HIV+ Children 7-11 Years Of Age.

Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] L1 Virus-Like Particle [VLP] Vaccine (Gardasil¿) In HIV-Infected Children > 7 to < 12 Years of Age

Study Status

Concluded

DAIDS Number

10163

IND Number

BB 13027

Study Chair

Study Vice-Chair

Data Manager

Drug Co. Representative

Field Representative

Immunologist

Investigator

Laboratory Technologist

Medical Officer

Protocol Pharmacist

Statistician

Virologist

Westat Representative

Abstracts

Safety and immunogenicity of a quadrivalent vaccine to prevent human papilloma virus (HPV) infection in HIV-infected children: IMPAACT P1047.

Conference

15th Conference on Retroviruses & Opportunistic Infections

Study

P1047

Authors

Adriana Weinberg, Lin-Ye Song, Edward Handelsman, Anna-Barbara Moscicki, Julie A. Patterson, Alfred J. Saah, David Radley, Jennifer S. Read, Myron Levin

Magnitude and persistence of humoral, mucosal and cell-mediated immunity (CMI) after administering quadrivalent human papillomavirus vaccine (QHPV) to HIV+ children and cross-reactivity with nonvaccine serotypes

Study

P1047

Safety and immunogenicity of Gardasil in HIV-infected children.

Conference

25th International Papillomavirus Conference

Study

P1047

Authors

Anna-Barbara Moscicki, Adriana Weinberg, Lin-Ye Song, Edward Handelsman, Julie A. Patterson, Alfred J. Saah, David Radley, Jennifer S. Read, Carlos A. Sattler, Myron Levin